BR122017025423B1
(pt)
|
2011-04-08 |
2021-05-11 |
Janssen Sciences Ireland Uc |
derivados de pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
|
SG11201401244TA
(en)
|
2011-11-09 |
2014-09-26 |
Janssen R & D Ireland |
Purine derivatives for the treatment of viral infections
|
DK2872515T3
(en)
|
2012-07-13 |
2016-09-19 |
Janssen Sciences Ireland Uc |
MACROCYCLIC PURINES FOR TREATING VIRUS INFECTIONS
|
NZ705589A
(en)
|
2012-10-10 |
2019-05-31 |
Janssen Sciences Ireland Uc |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
MY171115A
(en)
|
2012-11-16 |
2019-09-26 |
Janssen Sciences Ireland Uc |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
CN105189468B
(zh)
|
2013-02-21 |
2018-10-30 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的2-氨基嘧啶衍生物
|
CN110590809B
(zh)
|
2013-03-29 |
2022-04-19 |
爱尔兰詹森科学公司 |
用于治疗病毒感染的大环脱氮-嘌呤酮
|
ES2657283T3
(es)
|
2013-05-24 |
2018-03-02 |
Janssen Sciences Ireland Uc |
Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
|
SG10201803331PA
(en)
|
2013-06-27 |
2018-06-28 |
Janssen Sciences Ireland Uc |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
WO2015014815A1
(en)
|
2013-07-30 |
2015-02-05 |
Janssen R&D Ireland |
THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
|
PT3321265T
(pt)
|
2015-03-04 |
2020-07-07 |
Gilead Sciences Inc |
Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll
|
US20210292327A1
(en)
|
2015-08-26 |
2021-09-23 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
AU2016322763A1
(en)
|
2015-09-15 |
2018-04-19 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of HIV
|
UA125819C2
(uk)
|
2015-12-15 |
2022-06-15 |
Гіліад Сайєнсіз, Інк. |
ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
|
KR102202984B1
(ko)
|
2016-05-27 |
2021-01-13 |
길리애드 사이언시즈, 인코포레이티드 |
Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
SG11201811448RA
(en)
|
2016-07-01 |
2019-01-30 |
Janssen Sciences Ireland Unlimited Co |
Dihydropyranopyrimidines for the treatment of viral infections
|
DE102016212307B4
(de)
|
2016-07-06 |
2018-02-22 |
Thyssenkrupp Ag |
Verfahren zur Herstellung einer Zahnstange für ein Kraftfahrzeug, sowie Zahnstange für ein Lenkgetriebe
|
DE102016212303A1
(de)
|
2016-07-06 |
2018-01-11 |
Thyssenkrupp Ag |
Zahnstange und ein Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs
|
DE102016212308B4
(de)
|
2016-07-06 |
2018-02-22 |
Thyssenkrupp Ag |
Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs, sowie Zahnstange
|
DE102016212304B4
(de)
|
2016-07-06 |
2018-02-22 |
Thyssenkrupp Ag |
Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs, sowie Zahnstange
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
SI3507276T1
(sl)
|
2016-09-02 |
2022-01-31 |
Gilead Sciences, Inc. |
Spojine modulatorja toličnih receptorjev
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
WO2018060317A1
(en)
|
2016-09-29 |
2018-04-05 |
Janssen Sciences Ireland Uc |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
CR20190181A
(es)
|
2016-10-14 |
2019-08-21 |
Prec Biosciences Inc |
Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
|
US10662161B2
(en)
|
2017-01-30 |
2020-05-26 |
Regents Of The University Of Minnesota |
Pyrimidines and uses thereof
|
TWI868958B
(zh)
|
2017-01-31 |
2025-01-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
TW202024061A
(zh)
*
|
2017-08-17 |
2020-07-01 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
EP3672970A1
(en)
|
2017-08-22 |
2020-07-01 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
AU2018385693A1
(en)
|
2017-12-15 |
2020-06-18 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
EP3728282B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CN118084940A
(zh)
|
2018-02-13 |
2024-05-28 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
CN111836805B
(zh)
|
2018-02-15 |
2023-07-14 |
吉利德科学公司 |
吡啶衍生物及其用于治疗hiv感染的用途
|
EP4253366A3
(en)
|
2018-02-16 |
2023-11-29 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
|
CA3091142C
(en)
|
2018-02-26 |
2023-04-11 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds and uses thereof
|
TW202415645A
(zh)
|
2018-03-01 |
2024-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
US10899735B2
(en)
|
2018-04-19 |
2021-01-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
KR102579246B1
(ko)
|
2018-07-03 |
2023-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
HIV gp120을 표적화하는 항체 및 사용 방법
|
EP3818052A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2020010223A1
(en)
|
2018-07-06 |
2020-01-09 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
KR102625712B1
(ko)
|
2018-07-13 |
2024-01-19 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
CN120078775A
(zh)
|
2018-07-16 |
2025-06-03 |
吉利德科学公司 |
用于治疗hiv的衣壳抑制剂
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
AU2019339344A1
(en)
|
2018-09-12 |
2021-03-18 |
Silverback Therapeutics, Inc. |
Compositions for the treatment of disease with immune stimulatory conjugates
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
IL282535B2
(en)
|
2018-10-31 |
2024-05-01 |
Gilead Sciences Inc |
Transformed 6-azabanzimidazole compounds as HPK1 inhibitors
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
CA3129011C
(en)
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
KR102714084B1
(ko)
|
2019-03-22 |
2024-10-08 |
길리애드 사이언시즈, 인코포레이티드 |
가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
WO2020257407A1
(en)
|
2019-06-19 |
2020-12-24 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
CA3142513A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
CA3145791A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
IL315295A
(en)
|
2019-09-30 |
2024-10-01 |
Gilead Sciences Inc |
Hbv vaccines and methods treating hbv
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
EP4349413A3
(en)
|
2019-10-18 |
2024-06-26 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
US11807625B2
(en)
|
2019-11-26 |
2023-11-07 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of HIV
|
EP4567109A2
(en)
|
2019-12-06 |
2025-06-11 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
SI4081305T1
(sl)
|
2019-12-24 |
2025-03-31 |
Carna Biosciences, Inc. |
Spojine, ki modulirajo diacilglicerol kinazo
|
AU2021219668B2
(en)
|
2020-02-14 |
2025-06-12 |
Gilead Sciences, Inc. |
Antibodies and fusion proteins that bind to CCR8 and uses thereof
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
CA3169348A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
CA3181922A1
(en)
|
2020-05-01 |
2021-11-04 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
EP4153181A1
(en)
|
2020-05-21 |
2023-03-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
AU2021296607B2
(en)
|
2020-06-25 |
2024-07-25 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
AU2021300362A1
(en)
|
2020-07-01 |
2023-02-23 |
ARS Pharmaceuticals, Inc. |
Anti-ASGR1 antibody conjugates and uses thereof
|
MX2023001507A
(es)
|
2020-08-07 |
2023-03-06 |
Gilead Sciences Inc |
Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
US20220144923A1
(en)
|
2020-11-11 |
2022-05-12 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
EP4326768A1
(en)
|
2021-04-23 |
2024-02-28 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
WO2022241134A1
(en)
|
2021-05-13 |
2022-11-17 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
Diacylglyercol kinase modulating compounds
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
CN118139858A
(zh)
|
2021-10-28 |
2024-06-04 |
吉利德科学公司 |
吡地嗪-3(2h)-酮衍生物
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
DK4440702T3
(da)
|
2021-12-03 |
2025-08-18 |
Gilead Sciences Inc |
Terapeutiske forbindelser til hiv-virusinfektion
|
US12084467B2
(en)
|
2021-12-03 |
2024-09-10 |
Gilead Sciences, Inc. |
Therapeutic compounds for HIV virus infection
|
US12404262B2
(en)
|
2021-12-03 |
2025-09-02 |
Gilead Sciences, Inc. |
Therapeutic compounds for HIV virus infection
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
KR20240125012A
(ko)
|
2021-12-22 |
2024-08-19 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ikaros鋅指家族降解劑及其用途
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
TWI856796B
(zh)
|
2022-04-06 |
2024-09-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
EP4547659A1
(en)
|
2022-07-01 |
2025-05-07 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
CN119677546A
(zh)
|
2022-07-12 |
2025-03-21 |
吉利德科学公司 |
Hiv免疫原性多肽和疫苗及其用途
|
KR20250051732A
(ko)
|
2022-08-26 |
2025-04-17 |
길리애드 사이언시즈, 인코포레이티드 |
광범위 중화 항체를 위한 투여 및 일정 요법
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
EP4598934A1
(en)
|
2022-10-04 |
2025-08-13 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
WO2024137852A1
(en)
|
2022-12-22 |
2024-06-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
WO2024220624A1
(en)
|
2023-04-19 |
2024-10-24 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
US20250011352A1
(en)
|
2023-05-31 |
2025-01-09 |
Gilead Sciences, Inc. |
Solid forms
|
US20250042926A1
(en)
|
2023-05-31 |
2025-02-06 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
TW202515549A
(zh)
|
2023-10-11 |
2025-04-16 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
US20250127801A1
(en)
|
2023-10-11 |
2025-04-24 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
WO2025080863A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|